Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of 2 new real‐time polymerase chain reaction–based urinary markers in the follow‐up of patients with non–muscle‐invasive bladder cancer

24 Jan 2020

Abstract excerpt

BACKGROUND: The objective of the current study was to compare the diagnostic accuracy of 2 new real-time polymerase chain reaction-based urinary markers with each other and with urinary cytology, cystoscopy, and/or histology in patients being followed for non-muscle-invasive bladder cancer. METHODS: A total of 487 patients were enrolled in the study. Patients were evaluated using voided urine cytology, the Xpert...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Urinary and Genital Oncology Studies
Share to Urinary Tract Infections Management

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31977131
DOI: 10.1002/cncy.22246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of 2 new real‐time polymerase chain reaction–based urinary markers in the follow‐up of patients with non–muscle‐invasive bladder cancerPMID 31977131Read ↗

Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer.Semantic proximity Read ↗

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.Semantic proximity Read ↗

Roles for epigenetic and other biomarkers in upper tract urothelial carcinoma diagnosis and surveillanceSemantic proximity Read ↗

Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Semantic proximity Read ↗

Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and SurveillanceSemantic proximity Read ↗

Urinary Biomarkers in Urothelial Carcinoma: Expanded Con-temporary Evidence for Diagnosis, Surveillance, Risk Stratification, and Cystoscopy-Sparing Clinical PathwaysSemantic proximity Read ↗

Molecular markers for detection, surveillance and prognostication of bladder cancer.Semantic proximity Read ↗

Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAsSemantic proximity Read ↗

Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkersSemantic proximity Read ↗

Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder CancerSemantic proximity Read ↗

Uromonitor <sup>®</sup> as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancerSemantic proximity Read ↗

Non-invasive detection of bladder cancer through the analysis of driver gene mutations and aneuploidySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.